newsfilter
← Latest News
GlobeNewswire·

Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update

Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q3 revenues of $143.9 million, +45% versus Q3 of 2025, and +11% versus Q2 of 2026, driven by strong demand growthRaised 2026 full-year net product